Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality

European Heart Journal

Volumn 35, Issue 18, 2014, Pages 1215-1221

  Haring, Robin ^a   Friedrich, Nele ^a   Völzke, Henry ^a   Vasan, Ramachandran S ^b,c   Felix, Stephan B ^a   Dörr, Marcus ^a   Meyer Zu Schwabedissen, Henriette E ^a   Nauck, Matthias ^a   Wallaschofski, Henri ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Cardiovascular disease; Mortality; Population based cohort; Prolactin

Indexed keywords

PROLACTIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; SURVIVAL TIME; WAIST CIRCUMFERENCE; BLOOD; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; EPIDEMIOLOGY; GERMANY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROLACTIN; YOUNG ADULT;

EID: 84900296692     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs233     Document Type: Article

References (48)

1. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrin Metab 2006;17:110-116.
2. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998;19:225-268.
3. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80:1523-1631.
4. Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 2006;64:366-370.
5. Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gozu H, Sezgin O, Haklar G, Akalin S. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolac-tinemic pre-menopausal women. Eur J Endocrinol 2003;149:187-193.
6. Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, Lykka M, Kyrkou K, Rizos D, Creatsa M, Christodoulakos G, Alevizaki M, Sfikakis PP, Papamichael C. Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 2009;54:98-105.
7. Zhang L, Curhan GC, Forman JP. Plasma prolactin level and risk of incident hypertension in postmenopausal women. J Hypertens 2010;28:1400-1405.
8. Friedrich N, Schneider HJ, Spielhagen C, Markus MR, Haring R, Grabe HJ, Buchfelder M, Wallaschofski H, Nauck M. The association of serum prolactin concentration with inflammatory biomarkers-cross-sectional findings from the population-based Study of Health in Pomerania. Clin Endocrinol (Oxf) 2011;75: 561-566.
9. Friedrich N, Rosskopf D, Brabant G, Volzke H, Nauck M, Wallaschofski H. Associations of anthropometric parameters with serum TSH, prolactin, IGF-I, and testosterone levels: results of the Study of Health in Pomerania (SHIP). Exp Clin Endocrinol Diabetes 2010;118:266-273.
10. Haring R, Alte D, Volzke H, Sauer S, Wallaschofski H, John U, Schmidt CO. Extended recruitment efforts minimize attrition but not necessarily bias. J Clin Epidemiol 2009;62:252-260.
11. Völzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, Aumann N, Lau K, Piontek M, Born G, Havemann C, Ittermann T, Schipf S, Haring R, Baumeister SE, Wallaschofski H, Nauck M, Frick S, Arnold A, Junger M, Mayerle J, Kraft M, Lerch MM, Dorr M, Reffelmann T, Empen K, Felix SB, Obst A, Koch B, Glaser S, Ewert R, Fietze I, Penzel T, Doren M, Rathmann W, Haerting J, Hannemann M, Ropcke J, Schminke U, Jurgens C, Tost F, Rettig R, Kors JA, Ungerer S, Hegenscheid K, Kuhn JP, Kuhn J, Hosten N, Puls R, Henke J, Gloger O, Teumer A, Homuth G, Volker U, Schwahn C, Holtfreter B, Polzer I, Kohlmann T, Grabe HJ, Rosskopf D, Kroemer HK, Kocher T, Biffar R, John U, Hoffmann W. Cohort profile: the Study of Health in Pomerania. Int J Epidemiol 2011;40:294-307.
12. Le Moli R, Endert E, Fliers E, Mulder T, Prummel MF, Romijn JA, Wiersinga WM. Establishment of reference values for endocrine tests. II: hyperprolactinemia. Neth J Med 1999;55:71-75.
13. Luepker R, Evans A, McKeigue P, Reddy KS. Cardiovascular survey methods. 3rd ed. Geneva: World Health Organization, 2004.
14. NYHA. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, MA, USA: Little, Brown & Co; 1994. p253-255.
15. Torkler S, Wallaschofski H, Baumeister SE, Volzke H, Dorr M, Felix S, Rettig R, Nauck M, Haring R. Inverse association between total testosterone concentrations, incident hypertension and blood pressure. Aging Male. 2011;14:176-182.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461-470.
17. Haring R, Volzke H, Steveling A, Krebs A, Felix SB, Schofl C, Dorr M, Nauck M, Wallaschofski H. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J. 2010;31:1494-1501.
18. Friedrich N, Milman N, Volzke H, Linneberg A, Jorgensen T. Is serum ferritin within the reference range a risk predictor of cardiovascular disease? A population-based, long-term study comprising 2874 subjects. Br J Nutr 2009; 102:594-600.
19. Stone C, Koo C. Additive splines in statistics. In: Proceedings of the American Statistical Computing Section. Washington, DC: American Statistical Association. 1985, p45-48.
20. Cox DR. Regression models and life-tables. J R Stat Soc Ser B (Methodol) 1972;34: 187-220.
21. Cleves M, Gould WW, Gutierrez RG, Marchenko Y. An Introduction to Survival Analysis using Stata. 2nd ed. College Station, TX, USA: Stata Press; 2008.
22. Molitch ME. Drugs and prolactin. Pituitary 2008;11:209-218.
23. Afifi AA, Kotlerman JB, Ettner SL, Cowan M. Methods for improving regression analysis for skewed continuous or counted responses. Ann Rev Public Health 2007;28:95-111.
24. Vittinghoff E, Shiboski S, Glidden D. Regression Methods for Biostatistics: Linear, Logistic, Survival and Repeated Measures Models. New York: Springer; 2005.
25. Wallaschofski H, Donne M, Eigenthaler M, Hentschel B, Faber R, Stepan H, Koksch M, Lohmann T. PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab 2001;86:5912-5919.
26. Wallaschofski H, Kobsar A, Koksch M, Siegemund A, Hentschel B, Tuschy U, Lohmann T, Sokolova O, Eigenthaler M. Prolactin receptor signaling during platelet activation. Horm Metab Res 2003;35:228-235.
27. Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol (Oxf) 2010;73: 502-507.
28. Wallaschofski H, Kobsar A, Sokolova O, Eigenthaler M, Lohmann T. Co-activation of platelets by prolactin or leptin-athophysiological findings and clinical implications. Horm Metab Res 2004;36:1-6.
29. Raaz D, Wallaschofski H, Stumpf C, Yilmaz A, Cicha I, Klinghammer L, Daniel WG, Lohmann T, Garlichs CD. Increased prolactin in acute coronary syndromes as putative co-activator of ADP-stimulated P-selectin expression. Horm Metab Res 2006;38:767-772.
30. van Zaane B, Reuwer AQ, Buller HR, Kastelein JJ, Gerdes VE, Twickler MT. Hormones and cardiovascular disease: a shift in paradigm with clinical consequences? Semin Thromb Hemost 2009;35:478-487.
31. Sauro MD, Bing B, Zorn NE. Prolactin induces growth-related gene expression in rat aortic smooth muscle in vivo. Eur J Pharmacol 1992;225:351-354.
32. Sauro MD, Zorn NE. Prolactin induces proliferation of vascular smooth muscle cells through a protein kinase C-dependent mechanism. J Cell Physiol 1991;148: 133-138.
33. Molinari C, Grossini E, Mary DA, Uberti F, Ghigo E, Ribichini F, Surico N, Vacca G. Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology 2007;148:4080-4090.
34. Piwnica D, Touraine P, Struman I, Tabruyn S, Bolbach G, Clapp C, Martial JA, Kelly PA, Goffin V. Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance. Mol Endocrinol 2004;18:2522-2542.
35. Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, Weiner RI, Martial JA. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci USA 1999;96:1246-1251.
36. D'Angelo G, Martini JF, Iiri T, Fantl WJ, Martial J, Weiner RI. 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol Endocrinol 1999;13:692-704.
37. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, Luchtefeld M, Poli V, Schneider MD, Balligand JL, Desjardins F, Ansari A, Struman I, Nguyen NQ, Zschemisch NH, Klein G, Heusch G, Schulz R, Hilfiker A, Drexler H. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007;128:589-600.
38. Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 2002;173:219-238.
39. Selle T, Renger I, Labidi S, Bultmann I, Hilfiker-Kleiner D. Reviewing peripartum cardiomyopathy: current state of knowledge. Future Cardiol 2009;5:175-189.
40. Hilfiker-Kleiner D, Hilfiker A, Drexler H. Many good reasons to have STAT3 in the heart. Pharmacol Ther 2005;107:131-137.
41. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B, Hillmer A, Schmiedl A, Ding Z, Podewski E, Podewski E, Poli V, Schneider MD, Schulz R, ParkJK, Wollert KC, Drexler H. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 2004;95: 187-195.
42. Reuwer AQ, van Eijk M, Houttuijn-Bloemendaal FM, van der Loos CM, Claessen N, Teeling P, Kastelein JJ, Hamann J, Goffin V, von der Thusen JH, Twickler MT, Aten J. The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogen-esis? J Endocrinol 2011;208:107-117.
43. Corona G, Rastrelli G, Boddi V, Monami M, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction. IntJ Androl 2010;33:1-8.
44. Reuwer AQ, Twickler MT, Hutten BA, Molema FW, Wareham NJ, Dallinga-Thie GM, Bogorad RL, Goffin V, Smink-Bol M, Kastelein JJ, Boekholdt SM, Khaw KT. Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circulation 2009;2:389-395.
45. Corona G, Mannucci EJannini EA, Lotti F, Ricca V, Monami M, Boddi V, Bandini E, Balercia G, Forti G, Maggi M. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med 2009;6:1457-1466.
46. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health 2005;95(Suppl. 1):S144-S150.
47. Katznelson L, Riskind PN, Saxe VC, Klibanski A. Prolactin pulsatile characteristics in postmenopausal women. J Clin Endocrinol Metab 1998;83:761-764.
48. Davis CE, Rifkind BM, Brenner H, Gordon DJ. A single cholesterol measurement underestimates the risk of coronary heart disease. An empirical example from the lipid research clinics mortality follow-up study. JAMA 1990; 264:3044-3046.